Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Validation of a Mouse Model of Pancreatic Carcinogenesis
BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis
Status: Enrolling
Updated:  7/2/2012
Columbia University Medical Center
mi
from
New York, NY
Validation of a Mouse Model of Pancreatic Carcinogenesis
BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis
Status: Enrolling
Updated: 7/2/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Status: Enrolling
Updated:  7/3/2012
Johns Hopkins Hospital
mi
from
Baltimore, MD
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Status: Enrolling
Updated: 7/3/2012
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
University of Alabama at Birminghamn Dept. of Pediatric-Hematology/Oncology
mi
from
Birmingham, AL
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
University of Alabama at Birminghamn Dept. of Pediatric-Hematology/Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Center for Cancer and Blood Disorders-Phoenix Children's Hospital
mi
from
Phoenix, AZ
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Center for Cancer and Blood Disorders-Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Children's Hospital of Orange County (CHOC)
mi
from
Orange, CA
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Children's Hospital of Orange County (CHOC)
mi
from
Orange, CA
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Stanford University and Lucile Packard Children's Hospital
mi
from
Palo Alto, CA
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Stanford University and Lucile Packard Children's Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Children's HospitalCenter for Cancer and Blood Disorders
mi
from
Aurora, CO
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Children's HospitalCenter for Cancer and Blood Disorders
mi
from
Aurora, CO
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Children's National Medical Center - D.C. Center for Cancer and Blood Disorders
mi
from
Washington,
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Children's National Medical Center - D.C. Center for Cancer and Blood Disorders
mi
from
Washington,
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
University of Florida Shands Children's Hospital
mi
from
Gainesville, FL
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
University of Florida Shands Children's Hospital
mi
from
Gainesville, FL
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
University of Miami
mi
from
Miami, FL
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Emory UniversityChildren's Healthcare of AtlantaAflac Cancer Center & Blood Disorders
mi
from
Atlanta, GA
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Emory UniversityChildren's Healthcare of AtlantaAflac Cancer Center & Blood Disorders
mi
from
Atlanta, GA
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Children's Memorial Medical Hospital
mi
from
Chicago, IL
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Children's Memorial Medical Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Johns Hopkins UniversitySchool of Medicine
mi
from
Baltimore, MD
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Johns Hopkins UniversitySchool of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology
mi
from
Boston, MA
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology
mi
from
Boston, MA
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Amplatz Children's Hospital Univeristy of Minnesota Medical Center- Pediatric Hematology Oncology
mi
from
Minneapolis, MN
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Amplatz Children's Hospital Univeristy of Minnesota Medical Center- Pediatric Hematology Oncology
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Columbia University Children's Hospital of New York Presbyterian Child & Adolescent Oncology Center
mi
from
New York, NY
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Columbia University Children's Hospital of New York Presbyterian Child & Adolescent Oncology Center
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Steven D Hassenfeld Children's Center - New York University
mi
from
New York, NY
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Steven D Hassenfeld Children's Center - New York University
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Oregon Health & Sciences UniversityDoembecher Children's Hospital
mi
from
Portland, OR
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Oregon Health & Sciences UniversityDoembecher Children's Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
Children's Medical Center Dallas, Center for Cancer and Blood Disorders
mi
from
Dallas, TX
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
Children's Medical Center Dallas, Center for Cancer and Blood Disorders
mi
from
Dallas, TX
Click here to add this to my saved trials
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated:  7/3/2012
University of WisconsinPediatric Hematology/Oncology Department
mi
from
Madison, WI
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status: Enrolling
Updated: 7/3/2012
University of WisconsinPediatric Hematology/Oncology Department
mi
from
Madison, WI
Click here to add this to my saved trials
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Status: Enrolling
Updated:  7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Status: Enrolling
Updated: 7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Status: Enrolling
Updated:  7/5/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Status: Enrolling
Updated: 7/5/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
Status: Enrolling
Updated:  7/5/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
Status: Enrolling
Updated: 7/5/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Status: Enrolling
Updated:  7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Status: Enrolling
Updated: 7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Status: Enrolling
Updated:  7/9/2012
Stanford University School of Medicine
mi
from
Stanford, CA
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Status: Enrolling
Updated: 7/9/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Tesetaxel for Previously Treated Patients With Bladder Cancer
A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium
Status: Enrolling
Updated:  7/9/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Tesetaxel for Previously Treated Patients With Bladder Cancer
A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium
Status: Enrolling
Updated: 7/9/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Tesetaxel for Previously Treated Patients With Bladder Cancer
A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium
Status: Enrolling
Updated:  7/9/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Tesetaxel for Previously Treated Patients With Bladder Cancer
A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium
Status: Enrolling
Updated: 7/9/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy
Status: Enrolling
Updated:  7/9/2012
The Mount Sinai Medical Center, Otolaryngology - Head and Neck Surgery
mi
from
New York, NY
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy
Status: Enrolling
Updated: 7/9/2012
The Mount Sinai Medical Center, Otolaryngology - Head and Neck Surgery
mi
from
New York, NY
Click here to add this to my saved trials
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/10/2012
Montefiore Medical Center
mi
from
Bronx, NY
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/10/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/10/2012
Cancer Therapy and Research Center at UTHSCSA
mi
from
San Antonio, TX
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/10/2012
Cancer Therapy and Research Center at UTHSCSA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status: Enrolling
Updated:  7/10/2012
Yale Cancer Center
mi
from
New Haven, CT
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status: Enrolling
Updated: 7/10/2012
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Genesis Cancer Center
mi
from
Hot Springs, AR
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Genesis Cancer Center
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
City of Hope National Medical Center
mi
from
Duarte, CA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
UCLA Health System
mi
from
Santa Monica, CA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
UCLA Health System
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Rush University Medical Center
mi
from
Chicago, IL
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
University of Chicago Medical Center
mi
from
Chicago, IL
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Massachusetts General Hospital
mi
from
Boston, MA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
University of North Carolina Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Piedmont Hematology Oncology Associates PA
mi
from
Winston Salem, NC
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Piedmont Hematology Oncology Associates PA
mi
from
Winston Salem, NC
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Oregon Health and Science University
mi
from
Portland, OR
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/11/2012
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/11/2012
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
Click here to add this to my saved trials